Claims:

1. The use of a preparation based on an antibody directed against a tumor-associated antigen, for preparing a medicament for the intra-operative treatment of tumor patients by immunocomplexing of tumor cells within the scope of surgical interventions, the preparation being utilized for the prophylactic treatment to prevent dissemination of tumor cells.

2. The use according to claim 1, characterised in that the antibody is directed against an epitope of a surface antigen of a tumor cell.

3. The use according to claim 1 or 2, characterised in that the tumor cell is an epithelial tumor cell.

4. The use according to any one of claims 1 to 3, characterised in that the antibody is directed against an epitope of an antigen selected from the group of peptides or proteins, in particular EpCAM, NCAM, CEA, the carbohydrates, in particular Lewis Y, Sialyl-TN, Globo H, and the glycolipids, in particular GD2, GD3 and GM2.

5. The use according to any one of claims 1 to 4, characterised in that the antibody is used in an antibody mixture of various antibodies having a specificity for tumor-associated antigens.

6. The use according to any one of claims 1 to 5, characterised in that the antibody functionally activates the immune system, according to an ADCC and CDC effector function.

7. The use according to any one of claims 1 to 6, characterised in that the antibody binds to the tumor-associated antigen with an affinity corresponding to a dissociation constant below a Kd value of 10^{-6} mol/l, preferably less than 10^{-7} mol/l, most preferred 10^{-8} mol/l, or less.

8. The use according to any one of claims 1 to 7, characterised in that the antibody is derived from murine, chimeric, hu-

manized and/or human sources.

9. The use according to any one of claims 1 to 8, characterised in that the medicament is systemically used with a single dose of at least 50 mg, preferably at least 100 mg, most preferred at least 200 mg, to up to 2 g per patient.

10. The use according to any one of claims 1 to 9, characterised in that the medicament is locally applied to the tumor tissue and/or to the wound area.

11. The use according to any one of claims 1 to 10, characterised in that the medicament is administered immediately during or before, preferably within 24 hours, preferably within 4 hours, before the surgical intervention.

12. The use according to any one of claims 1 to 11, characterised in that the surgical intervention is carried out for a biopsy and/or for the removal of a solid tumor.

13. The use according to any one of claims 1 to 12, characterised in that the surgical intervention is carried out for a determination regarding the malignancy of a tumor.

14. The use according to any one of claims 1 to 13, characterised in that the antibody is determined on the immunocomplexed tumor tissue after the surgical intervention.

15. The use according to any one of claims 1 to 14, characterised in that the antibody is determined on tumor cells in blood or serum samples.

16. A kit for the intra-operative treatment of tumor patients, comprising
a) a medicament based on an antibody directed against a tumor-associated antigen, and
b) a means for the diagnostic determination of malignant tumor cells which are immunocomplexed with the antibody.